基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）对三阴性乳腺癌新辅助治疗反应的预测价值：一项系统综述和荟萃分析
英文原题：Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis.
查看英文原题
Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
TILs 可作为 TNBC 患者 NAT 治疗反应的预测指标。TILs 水平高的 TNBC 患者比 TILs 水平低的患者具有更高的 NAT pCR 率，且这种预测能力在不同 NAT 方案中保持一致。
研究思路结论见上方概要
背景
TIL（肿瘤浸润淋巴细胞）水平与三阴性乳腺癌（TNBC）患者新辅助治疗（NAT）反应之间的关联仍不明确。
目的
探讨TIL水平对TNBC患者NAT反应的预测潜力。
方法
对National Center for Biotechnology Information PubMed数据库进行了系统检索，以收集2023年8月31日之前发表的相关文献。采用系统评价和meta分析评估TNBC患者TIL水平与NAT病理完全缓解（pCR）之间的相关性。还进行了亚组分析、敏感性分析和发表偏倚分析。
结果
本meta分析共纳入32项研究。总体meta分析结果显示，高TIL亚组TNBC患者NAT治疗后的pCR率显著高于低TIL亚组患者（48.0% vs 27.7%）（风险比2.01；95%置信区间1.77-2.29；P < 0.001，I 2 = 56%）。亚组分析显示，研究间异质性来源于研究设计、TIL水平截断值和研究人群的差异。纳入研究中可能存在发表偏倚。基于不同NAT方案的meta分析显示，在所有方案中，高TIL水平的TNBC患者NAT治疗后的pCR率均更高（均P 0.01），不同NAT方案之间的统计学差异无显著性（P = 0.29）。此外，敏感性分析表明，逐一排除纳入研究后，meta分析的总体结果保持一致。
展开英文摘要原文
BACKGROUND
The association between tumor-infiltrating lymphocyte (TIL) levels and the response to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC) remains unclear. AIM: To investigate the predictive potential of TIL levels for the response to NAT in TNBC patients.
METHODS
A systematic search of the National Center for Biotechnology Information PubMed database was performed to collect relevant published literature prior to August 31, 2023. The correlation between TIL levels and the NAT pathologic complete response (pCR) in TNBC patients was assessed using a systematic review and meta-analysis. Subgroup analysis, sensitivity analysis, and publication bias analysis were also conducted.
RESULTS
A total of 32 studies were included in this meta-analysis. The overall meta-analysis results indicated that the pCR rate after NAT treatment in TNBC patients in the high TIL subgroup was significantly greater than that in patients in the low TIL subgroup (48.0% vs 27.7%) (risk ratio 2.01; 95% confidence interval 1.77-2.29; P < 0.001, I 2 = 56%). Subgroup analysis revealed that the between-study heterogeneity originated from differences in study design, TIL level cutoffs, and study populations. Publication bias could have existed in the included studies. The meta-analysis based on different NAT protocols revealed that all TNBC patients with high levels of TILs had a greater rate of pCR after NAT treatment in all protocols (all P 0.01), and there was no significant between-protocol difference in the statistics among the different NAT protocols ( P = 0.29). Additionally, sensitivity analysis demonstrated that the overall results of the meta-analysis remained consistent when the included studies were individually excluded.
CONCLUSION
TILs can serve as a predictor of the response to NAT treatment in TNBC patients. TNBC patients with high levels of TILs exhibit a greater NAT pCR rate than those with low levels of TILs, and this predictive capability is consistent across different NAT regimens.
论文信息
- 作者
- Sun HK、Jiang WL、Zhang SL、Xu PC、Wei LM、Liu JB
- 第一作者单位
- Department of Thyroid and Breast Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471000, Henan Province, China.China
- 通讯作者单位
- Department of Thyroid and Breast Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471000, Henan Province, China. jiangboliuxing@163.com.China
- 期刊
- World journal of clinical oncology2024 Jul 24
- 原文标识
- PubMed 39071463 · DOI 10.5306/wjco.v15.i7.920
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →